Bilateral Exudative Retinal Detachments Associated with Nivolumab Immunotherapy

Abstract

A 58-year-old Caucasian female presented to the retina service with a 2-week history of bilateral decrease in vision. She had stage 4 renal cell carcinoma with osseous metastasis and choroidal metastasis for which she has been treated with Nivolumab immunotherapy. Her exudative retinal detachments resolved after cessation of Nivolumab in association with subtenon steroids (STK) and intravitreal bevacizumab injections. To the best of our knowledge, this is the first report in the literature describing the resolution of Nivolumab-related exudative retinal detachment after early local therapy using STK injections (10 mg), bevacizumab intravitreal injections, and cessation of Nivolumab. We hope by sharing this report to provide new insight into the management of similar patients.

Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma

“…4 The ophthalmologic irAEs span a remarkably wide gamut, ranging from mild ocular surface dysfunction such as superficial punctate keratitis and conjunctivitis to severe posterior involvement with significant vision loss in the form of cystoid macular edema (CME), serous retinal detachments, birdshot chorioretinopathy, optic neuritis, and Vogt-Koyanagi-Harada (VKH) like syndromes among others. 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 …”